

Conflicts of Interest Document

For:

Urothelial bladder cancer extending to rectal mucosa via the prostate and mimicking hemorrhoidal bleeding with daily bright red blood per rectum coating stools: Novel case report and novel colonoscopic findings

By:

Andrew M. Aneese M.D., M.S.¹, Vinayata Manuballa D.O.², Mitul Amin, M.D.³, and Mitchell S. Cappell, M.D., Ph.D.⁴ (*Drs. Aneese and Cappell are equal, primary authors*)
Gastroenterology Resident¹, Gastroenterology Fellow², and Chief⁴, Division of Gastroenterology and Hepatology, Department of Medicine, William Beaumont Hospital, Royal Oak, MI, USA; Chairman, Department of Pathology³, William Beaumont Hospital, Royal Oak, MI, USA; and Professor of Anatomy³, and Professor of Medicine⁴, Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA

Conflicts of interest: None. In particular, Dr. Cappell, as a consultant of the United States Food and Drug Administration (FDA) Advisory Committee for Gastrointestinal Drugs, affirms that this paper does not discuss any proprietary, confidential, pharmaceutical data submitted to the FDA. Dr. Cappell is also a member of the speaker's bureau for AstraZeneca and Daiichi Sankyo, co-marketers of Movantik. This work does not discuss any drug manufactured or marketed by AstraZeneca or Daiichi Sankyo.